MicroRNA-372 Acts As a Double-edged Sword in Human Cancers

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 May 30

PMID 37251909

Authors

Fatemeh Tajik

Fatemeh Alian

Mohammad Yousefi

Ali Azadfallah

Aref Hoseini

Forogh Mohammadi

Maryam Karimi-Dehkordi

Shahin Alizadeh-Fanalou

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3'-UTR mRNAs and controlling gene expression at the post-transcriptional level. As an oncogene, miRNAs can either accelerate cancer progression or slow it down as a tumor suppressor. MicroRNA-372 (miR-372) has been found to have an abnormal expression in numerous human malignancies, implying that the miRNA plays a role in carcinogenesis. It is both increased and downregulated in various cancers, and it serves as both a tumor suppressor and an oncogene. This study examines the functions of miR-372 as well as the LncRNA/CircRNA-miRNA-mRNA signaling pathways in various malignancies and analyses its potential prognostic, diagnostic, and therapeutic implications.

Citing Articles

Comprehensive computational analysis of differentially expressed miRNAs and their influence on transcriptomic signatures in prostate cancer.

Aldakheel F, Alnajran H, Mateen A, Alduraywish S, AlQahtani M, Syed R Sci Rep. 2025; 15(1):3646.

PMID: 39881138 PMC: 11779938. DOI: 10.1038/s41598-025-85502-4.

Investigation of CST7 and hsa-miR-4793-5p gene expression in breast cancer.

Kalaki N, Ahmadzadeh M, Dehghan M, Rabori V, Davoudi S, Afkhami H Biochem Biophys Rep. 2024; 40:101863.

PMID: 39552709 PMC: 11566318. DOI: 10.1016/j.bbrep.2024.101863.

A new perspective on diagnostic strategies concerning the potential of saliva-based miRNA signatures in oral cancer.

Prasad M, Sekar R, Priya M, Varma S, Karobari M Diagn Pathol. 2024; 19(1):147.

PMID: 39548527 PMC: 11568613. DOI: 10.1186/s13000-024-01575-1.

Exploring the intricate relationship between miRNA dysregulation and breast cancer development: insights into the impact of environmental chemicals.

Abolhasanzadeh N, Sarabandi S, Dehghan B, Karamad V, Biray Avci C, Shademan B Front Immunol. 2024; 15:1333563.

PMID: 38807590 PMC: 11130376. DOI: 10.3389/fimmu.2024.1333563.

Impact of Mir196a-2 Genotypes on Colorectal Cancer Risk in Taiwan.

Yueh T, Wang Y, Chin Y, Hung Y, Mong M, Yang Y Int J Mol Sci. 2023; 24(14).

PMID: 37511371 PMC: 10380589. DOI: 10.3390/ijms241411613.

References

Zhao L, Bode A, Cao Y, Dong Z . Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis. 2012; 33(11):2220-7. PMC: 3483015. DOI: 10.1093/carcin/bgs235. View

Wang Z, Mao J, Liu G, Wang F, Ju Z, Zhou D . MicroRNA-372 enhances radiosensitivity while inhibiting cell invasion and metastasis in nasopharyngeal carcinoma through activating the PBK-dependent p53 signaling pathway. Cancer Med. 2019; 8(2):712-728. PMC: 6382924. DOI: 10.1002/cam4.1924. View

Tu H, Chang K, Cheng H, Liu C . Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas. Laryngoscope. 2015; 125(11):E365-70. DOI: 10.1002/lary.25464. View

Wu G, Wang Y, Lu X, He H, Liu H, Meng X . Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer. 2015; 15:182. PMC: 4379970. DOI: 10.1186/s12885-015-1214-0. View

Wang Q, Liu S, Zhao X, Wang Y, Tian D, Jiang W . MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma. Cancer Med. 2017; 6(6):1323-1330. PMC: 5463061. DOI: 10.1002/cam4.1026. View

Li Z, Li X, Xu D, Chen X, Li S, Zhang L . An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 2020; 54(1):e12936. PMC: 7791175. DOI: 10.1111/cpr.12936. View

Li Y, Liu J, Zhou J, Chen R, Cen C . LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis. Mol Med. 2020; 26(1):26. PMC: 7081592. DOI: 10.1186/s10020-020-00155-5. View

Ji S, Su X, Zhang H, Han Z, Zhao Y, Liu Q . MicroRNA-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting in renal cell carcinoma. Oncol Lett. 2019; 17(2):2400-2408. PMC: 6350190. DOI: 10.3892/ol.2018.9871. View

Gheytanchi E, Tajik F, Razmi M, Babashah S, Cho W, Tanha K . Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis. Cancer Cell Int. 2023; 23(1):10. PMC: 9862982. DOI: 10.1186/s12935-023-02851-8. View

10.

Voorhoeve P, le Sage C, Schrier M, Gillis A, Stoop H, Nagel R . A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124(6):1169-81. DOI: 10.1016/j.cell.2006.02.037. View

11.

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

12.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

13.

Yeh L, Liu C, Wong Y, Chang C, Lin S, Chang K . miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo. Oncotarget. 2015; 6(8):6062-75. PMC: 4467422. DOI: 10.18632/oncotarget.3340. View

14.

Cho W, Shin J, Kim J, Lee M, Hong K, Lee J . miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells. 2009; 28(6):521-7. DOI: 10.1007/s10059-009-0158-0. View

15.

Sheng G, Gao Y, Yang Y, Wu H . Osteosarcoma and Metastasis. Front Oncol. 2021; 11:780264. PMC: 8702962. DOI: 10.3389/fonc.2021.780264. View

16.

Sun H, Gao D . Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372. BMC Cancer. 2018; 18(1):1252. PMC: 6295097. DOI: 10.1186/s12885-018-5175-y. View

17.

Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P . Risk factors for lung cancer worldwide. Eur Respir J. 2016; 48(3):889-902. DOI: 10.1183/13993003.00359-2016. View

18.

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

19.

Pfister S, Remke M, Castoldi M, Bai A, Muckenthaler M, Kulozik A . Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2008; 117(4):457-64. DOI: 10.1007/s00401-008-0467-y. View

20.

Subramanyam D, Lamouille S, Judson R, Liu J, Bucay N, Derynck R . Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol. 2011; 29(5):443-8. PMC: 3685579. DOI: 10.1038/nbt.1862. View